Non-V600 BRAF mutated melanomas, compared to those with BRAF V600 mutations or BRAF WT tumors, had higher levels of immune cell infiltration, increased tumor mutation burden (TMB), and elevated expression of immune checkpoint and T cell exhaustion markers, indicating a potentially favorable response to combination immune checkpoint inhibitors (ICP

This study developed and validated a workflow for accurately determining the genetically inferred ancestry (GIA) of patients from comprehensive genomic profiling (CGP) sequencing results, which can enable ancestry-aware biomarker research and contribute to reducing cancer disparities and improving representation in clinical trials.

Comprehensive genomic and immune profiling of invasive breast cancers, including a lobular-enriched cohort and non-lobular cohort, revealed that lobular-enriched tumors had distinct molecular and immunologic characteristics.

The study shows that tumor tissues collected in vivo had a higher tumor immunogenicity signature and lower cellular proliferation signature compared to cell lines grown in culture, indicating that an active immune system and a vascularized environment contribute to decreased cancer cell proliferation.

ALK-positive lung adenocarcinomas are associated with a younger age at sequencing, lower tumor mutational burden, higher PD-L1 expression, and lower cancer testis antigen burden compared to ALK-wild-type, EGFR mutated, and KRAS

Distinct genomic alterations were identified in different gene expression and immunotherapy marker defined immune-response phenotypes, with tumor-dominant phenotype tumors having the highest number of enriched alterations.

Tumors of younger patients with NSCLC had distinct genomic profiles with more targetable alterations, but lower mutational burden and immunogenicity compared to older patient tumors.